The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Aurothioglucose results in decreased activity of DIO1 protein [Aurothioglucose results in decreased activity of DIO1 protein] which affects the metabolism of Triiodothyronine, Reverse
[Sodium Glutamate co-treated with Aurothioglucose] results in increased expression of LEP mRNA; [Sodium Glutamate co-treated with Aurothioglucose] results in increased expression of LEP protein Aurothioglucose results in increased expression of LEP mRNA; Aurothioglucose results in increased expression of LEP protein
bafilomycin A1 inhibits the reaction [EGF protein results in increased phosphorylation of AKT1S1 protein]; bafilomycin A1 inhibits the reaction [Lidocaine results in decreased expression of [MTOR protein binds to RPTOR protein binds to MLST8 protein binds to PRAS40 protein binds to DEPTOR protein]]
bafilomycin A1 promotes the reaction [Lipopolysaccharides results in increased degradation of APPL1 protein]; bafilomycin A1 promotes the reaction [Poly I-C results in increased degradation of APPL1 protein]
ATG5 protein affects the reaction [bafilomycin A1 promotes the reaction [gossypol acetic acid results in increased expression of MAP1LC3B protein modified form]] [bafilomycin A1 co-treated with Swainsonine] results in increased expression of ATG5 mRNA; [bafilomycin A1 co-treated with Swainsonine] results in increased lipidation of ATG5 protein
bafilomycin A1 results in decreased expression of BCL2 mRNA bafilomycin A1 promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]
bafilomycin A1 inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of BECN1 protein] [Swainsonine co-treated with bafilomycin A1] results in increased expression of BECN1 protein; bafilomycin A1 promotes the reaction [[lead acetate results in increased abundance of Lead] which results in increased expression of BECN1 protein] bafilomycin A1 results in increased expression of BECN1 protein
bafilomycin A1 inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA]
bafilomycin A1 inhibits the reaction [manganese chloride results in increased expression of BID protein modified form]; bafilomycin A1 inhibits the reaction [manganese chloride results in increased expression of BID protein] vistusertib affects the reaction [bafilomycin A1 results in increased cleavage of BID protein] bafilomycin A1 results in increased expression of BID protein modified form
bafilomycin A1 results in increased expression of BNIP3 mRNA; bafilomycin A1 results in increased expression of BNIP3 protein BNIP3 mutant form promotes the reaction [bafilomycin A1 results in increased cleavage of PARP1 protein]; capivasertib affects the reaction [bafilomycin A1 results in increased expression of BNIP3 protein]; Erlotinib Hydrochloride inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 protein]; Gefitinib inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 protein]; HIF1A mutant form inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 mRNA]; Lapatinib inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 mRNA]; vistusertib inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 protein]
bafilomycin A1 results in decreased activity of CASP3 protein bafilomycin A1 results in increased cleavage of CASP3 protein bafilomycin A1 inhibits the reaction [Cadmium results in increased cleavage of CASP3 protein] bafilomycin A1 results in increased activity of CASP3 protein [Swainsonine co-treated with bafilomycin A1] results in increased cleavage of CASP3 protein; bafilomycin A1 inhibits the reaction [manganese chloride results in increased cleavage of CASP3 protein]; bafilomycin A1 promotes the reaction [Hydrogen Peroxide results in increased expression of CASP3 protein modified form]; bafilomycin A1 promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein] [bafilomycin A1 co-treated with Cannabidiol] results in increased cleavage of CASP3 protein; [bafilomycin A1 co-treated with cobaltous chloride co-treated with TP53 gene mutant form] results in increased activity of CASP3 protein; [bafilomycin A1 co-treated with methanandamide] results in increased cleavage of CASP3 protein; [Cannabidiol co-treated with bafilomycin A1] results in increased cleavage of CASP3 protein; bafilomycin A1 inhibits the reaction [Soot analog results in increased expression of CASP3 protein]; bafilomycin A1 inhibits the reaction [tetrandrine results in increased cleavage of CASP3 protein]; bafilomycin A1 promotes the reaction [Atorvastatin results in increased cleavage of CASP3 protein]; bafilomycin A1 promotes the reaction [brazilin results in increased activity of CASP3 protein]; bafilomycin A1 promotes the reaction [fosbretabulin results in increased cleavage of CASP3 protein]; tin protoporphyrin IX inhibits the reaction [[bafilomycin A1 co-treated with Cannabidiol] results in increased cleavage of CASP3 protein]; tin protoporphyrin IX inhibits the reaction [[bafilomycin A1 co-treated with methanandamide] results in increased cleavage of CASP3 protein]; vistusertib affects the reaction [bafilomycin A1 results in increased cleavage of CASP3 protein]
bafilomycin A1 inhibits the reaction [manganese chloride results in increased cleavage of CASP8 protein] bafilomycin A1 inhibits the reaction [Cadmium results in increased cleavage of CASP8 protein]
bafilomycin A1 inhibits the reaction [manganese chloride results in increased cleavage of CASP9 protein] bafilomycin A1 inhibits the reaction [Soot analog results in increased expression of CASP9 protein]
bafilomycin A1 inhibits the reaction [[cobaltous chloride co-treated with TP53 gene mutant form] results in increased activity of CTSB protein]; bafilomycin A1 inhibits the reaction [Hydroxychloroquine affects the localization of CTSB protein]
bafilomycin A1 inhibits the reaction [CpG ODN 2216 results in increased expression of CXCL10 protein]; bafilomycin A1 inhibits the reaction [gardiquimod results in increased expression of CXCL10 protein]; bafilomycin A1 inhibits the reaction [Poly I-C results in increased expression of CXCL10 protein]
bafilomycin A1 results in increased expression of DDIT4 protein [EGF protein co-treated with bafilomycin A1] results in increased expression of DDIT4 protein
bafilomycin A1 inhibits the reaction [Lidocaine results in decreased expression of [MTOR protein binds to RPTOR protein binds to MLST8 protein binds to PRAS40 protein binds to DEPTOR protein]]
[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Arginine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Asparagine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Isoleucine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Leucine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Lysine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Methionine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Ornithine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Phenylalanine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Tyrosine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Valine; [bafilomycin A1 co-treated with EGF protein] results in increased abundance of Aspartic Acid; [bafilomycin A1 co-treated with EGF protein] results in increased abundance of Taurine; [EGF protein co-treated with bafilomycin A1] results in increased expression of DDIT4 protein; bafilomycin A1 inhibits the reaction [EGF protein results in increased activity of and results in increased phosphorylation of RPS6KB1 protein]; bafilomycin A1 inhibits the reaction [EGF protein results in increased phosphorylation of AKT1S1 protein]; bafilomycin A1 inhibits the reaction [EGF protein results in increased phosphorylation of EIF4EBP1 protein]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Arginine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Asparagine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Isoleucine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Leucine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Lysine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Methionine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Ornithine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Phenylalanine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Tyrosine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Valine]
bafilomycin A1 inhibits the reaction [EGF protein results in increased phosphorylation of EIF4EBP1 protein]; bafilomycin A1 inhibits the reaction [INS protein results in increased phosphorylation of EIF4EBP1 protein]
bafilomycin A1 inhibits the reaction [FASL protein affects the localization of Calcium] bafilomycin A1 inhibits the reaction [manganese chloride results in increased expression of FASLG protein]
bafilomycin A1 results in increased expression of HIF1A protein HIF1A mutant form inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 mRNA]; HIF1A mutant form promotes the reaction [bafilomycin A1 results in increased cleavage of PARP1 protein]; lapatinib inhibits the reaction [bafilomycin A1 results in increased expression of HIF1A protein]
bafilomycin A1 results in decreased expression of HMOX1 protein [bafilomycin A1 co-treated with methanandamide] results in increased expression of HMOX1 protein; [bafilomycin A1 co-treated with tin protoporphyrin IX] promotes the reaction [Cannabidiol results in increased expression of HMOX1 protein]; bafilomycin A1 inhibits the reaction [4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole results in increased expression of HMOX1 protein]
bafilomycin A1 results in decreased expression of IL1B mRNA [bafilomycin A1 co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in increased expression of IL1B protein; bafilomycin A1 inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with aluminum sulfate] results in increased secretion of IL1B protein]
bafilomycin A1 promotes the reaction [Palmitic Acid inhibits the reaction [INS1 protein results in increased uptake of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose]]
bafilomycin A1 inhibits the reaction [INS protein results in increased phosphorylation of EIF4EBP1 protein]; bafilomycin A1 inhibits the reaction [INS protein results in increased phosphorylation of RPS6KB1 protein]
[bafilomycin A1 co-treated with Swainsonine] results in increased expression of LAMP1 mRNA; [bafilomycin A1 co-treated with Swainsonine] results in increased expression of LAMP1 protein bafilomycin A1 results in increased expression of LAMP1 protein
bafilomycin A1 promotes the reaction [Uranium results in increased expression of MAP1LC3A protein] bafilomycin A1 inhibits the reaction [Lidocaine results in increased expression of MAP1LC3A protein] bafilomycin A1 results in increased expression of MAP1LC3A protein modified form
[bafilomycin A1 co-treated with Miconazole] results in increased expression of MAP1LC3B protein; [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone co-treated with bafilomycin A1] results in increased expression of MAP1LC3B mRNA; [TNF protein co-treated with bafilomycin A1] results in increased expression of MAP1LC3B protein alternative form; Acetylcysteine inhibits the reaction [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone promotes the reaction [bafilomycin A1 results in increased expression of MAP1LC3B protein]]; ATG5 protein affects the reaction [bafilomycin A1 promotes the reaction [gossypol acetic acid results in increased expression of MAP1LC3B protein modified form]]; bafilomycin A1 affects the reaction [Ammonium Chloride results in increased metabolism of MAP1LC3B protein]; bafilomycin A1 affects the reaction [AZD4547 affects the expression of MAP1LC3B protein modified form]; bafilomycin A1 affects the reaction [AZD8186 affects the expression of MAP1LC3B protein modified form]; bafilomycin A1 inhibits the reaction [Chloroquine results in increased lipidation of MAP1LC3B protein]; bafilomycin A1 promotes the reaction [[alpha-Chlorohydrin co-treated with Diosgenin] results in increased lipidation of MAP1LC3B protein]; bafilomycin A1 promotes the reaction [capivasertib results in increased expression of MAP1LC3B protein modified form]; bafilomycin A1 promotes the reaction [Curcumin results in increased lipidation of MAP1LC3B protein]; bafilomycin A1 promotes the reaction [ginsenoside Rg2 results in increased expression of MAP1LC3B protein modified form]; bafilomycin A1 promotes the reaction [gossypol acetic acid results in increased expression of MAP1LC3B protein modified form]; bafilomycin A1 promotes the reaction [metarrestin results in increased expression of MAP1LC3B protein modified form]; bafilomycin A1 promotes the reaction [Miconazole results in increased lipidation of MAP1LC3B protein]; bafilomycin A1 promotes the reaction [ovatodiolide results in increased lipidation of MAP1LC3B protein]; bafilomycin A1 promotes the reaction [Particulate Matter results in increased expression of MAP1LC3B protein]; bafilomycin A1 promotes the reaction [Resveratrol results in increased expression of MAP1LC3B protein alternative form]; bafilomycin A1 promotes the reaction [Sevoflurane results in increased lipidation of MAP1LC3B protein]; bafilomycin A1 promotes the reaction [vistusertib results in increased expression of MAP1LC3B protein modified form]; bafilomycin A1 results in increased expression of and results in increased lipidation of MAP1LC3B protein; di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone promotes the reaction [bafilomycin A1 results in increased expression of MAP1LC3B protein]; Resveratrol promotes the reaction [[TNF protein co-treated with bafilomycin A1] results in increased expression of MAP1LC3B protein alternative form] bafilomycin A1 results in increased lipidation of MAP1LC3B protein [Doxorubicin co-treated with bafilomycin A1] results in increased expression of MAP1LC3B protein; [Glycyrrhizic Acid co-treated with bafilomycin A1] results in increased lipidation of MAP1LC3B protein; bafilomycin A1 inhibits the reaction [olaparib inhibits the reaction [Hydrogen Peroxide results in increased lipidation of MAP1LC3B protein]]; bafilomycin A1 promotes the reaction [C1QTNF9 protein results in increased expression of MAP1LC3B protein modified form] bafilomycin A1 results in increased expression of MAP1LC3B protein modified form [bafilomycin A1 co-treated with Swainsonine] results in increased expression of MAP1LC3B mRNA; [bafilomycin A1 co-treated with Swainsonine] results in increased lipidation of MAP1LC3B protein; bafilomycin A1 promotes the reaction [tricalcium phosphate results in increased expression of MAP1LC3B protein]; bafilomycin A1 promotes the reaction [Triiodothyronine results in increased lipidation of MAP1LC3B protein]; Triiodothyronine promotes the reaction [bafilomycin A1 results in increased lipidation of MAP1LC3B protein] bafilomycin A1 results in increased cleavage of MAP1LC3B protein bafilomycin A1 results in decreased degradation of MAP1LC3B protein modified form bafilomycin A1 results in increased expression of MAP1LC3B protein; bafilomycin A1 results in increased expression of MAP1LC3B protein alternative form; bafilomycin A1 results in increased expression of MAP1LC3B protein modified form
bafilomycin A1 inhibits the reaction [Capsaicin results in increased activity of MAPK1 protein]; bafilomycin A1 inhibits the reaction [Iron Compounds results in increased expression of MAPK1 protein modified form]; bafilomycin A1 promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased phosphorylation of MAPK1 protein] bafilomycin A1 results in increased expression of MAPK1 protein modified form
bafilomycin A1 inhibits the reaction [Capsaicin results in increased activity of MAPK3 protein]; bafilomycin A1 inhibits the reaction [Iron Compounds results in increased expression of MAPK3 protein modified form]; bafilomycin A1 promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased phosphorylation of MAPK3 protein] bafilomycin A1 results in increased expression of MAPK3 protein modified form
bafilomycin A1 inhibits the reaction [Lidocaine results in decreased expression of [MTOR protein binds to RPTOR protein binds to MLST8 protein binds to PRAS40 protein binds to DEPTOR protein]]
bafilomycin A1 results in decreased phosphorylation of MTOR protein bafilomycin A1 inhibits the reaction [Lidocaine results in decreased expression of [MTOR protein binds to RPTOR protein binds to MLST8 protein binds to PRAS40 protein binds to DEPTOR protein]]
bafilomycin A1 promotes the reaction [[Particulate Matter co-treated with Vitamin D] results in increased expression of NFE2L2 protein]; bafilomycin A1 promotes the reaction [[Silicon Dioxide co-treated with Vitamin D] results in increased expression of NFE2L2 protein]; bafilomycin A1 promotes the reaction [Particulate Matter results in increased expression of NFE2L2 protein]; bafilomycin A1 promotes the reaction [Silicon Dioxide results in increased expression of NFE2L2 protein] bafilomycin A1 results in increased expression of NFE2L2 protein
bafilomycin A1 inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of NLRP3 protein] bafilomycin A1 results in increased expression of NLRP3 protein
[Cysteine Proteinase Inhibitors results in decreased activity of USP8 protein] promotes the reaction [bafilomycin A1 results in increased cleavage of PARP1 protein]; bafilomycin A1 promotes the reaction [[Cysteine Proteinase Inhibitors results in decreased activity of USP8 protein] which results in increased cleavage of PARP1 protein]; bafilomycin A1 promotes the reaction [Atorvastatin results in increased cleavage of PARP1 protein]; bafilomycin A1 promotes the reaction [brazilin results in increased expression of PARP1 protein modified form]; bafilomycin A1 promotes the reaction [Flavanones results in increased cleavage of PARP1 protein]; bafilomycin A1 promotes the reaction [fosbretabulin results in increased cleavage of PARP1 protein]; BNIP3 mutant form promotes the reaction [bafilomycin A1 results in increased cleavage of PARP1 protein]; HIF1A mutant form promotes the reaction [bafilomycin A1 results in increased cleavage of PARP1 protein] bafilomycin A1 promotes the reaction [Methamphetamine results in increased cleavage of PARP1 protein] bafilomycin A1 inhibits the reaction [Cadmium results in increased cleavage of PARP1 protein] bafilomycin A1 results in increased expression of PARP1 protein modified form
bafilomycin A1 inhibits the reaction [2-chloroethyl ethyl sulfide results in decreased expression of PRKAA1 protein] bafilomycin A1 inhibits the reaction [Lidocaine results in increased phosphorylation of PRKAA1 protein]
[PRKD2 protein affects the susceptibility to [erastin co-treated with bafilomycin A1]] which affects the abundance of Malondialdehyde; bafilomycin A1 affects the reaction [[PRKD2 protein affects the susceptibility to erastin] which affects the expression of FTH1 protein]; bafilomycin A1 affects the reaction [[PRKD2 protein affects the susceptibility to erastin] which affects the expression of FTL protein]; bafilomycin A1 affects the reaction [[PRKD2 protein affects the susceptibility to erastin] which affects the expression of NCOA4 protein]; PRKD2 protein affects the susceptibility to [erastin co-treated with bafilomycin A1]
bafilomycin A1 results in decreased phosphorylation of RPS6KB1 protein bafilomycin A1 inhibits the reaction [EGF protein results in increased activity of and results in increased phosphorylation of RPS6KB1 protein]; bafilomycin A1 inhibits the reaction [INS protein results in increased phosphorylation of RPS6KB1 protein]
bafilomycin A1 inhibits the reaction [Lidocaine results in decreased expression of [MTOR protein binds to RPTOR protein binds to MLST8 protein binds to PRAS40 protein binds to DEPTOR protein]]
bafilomycin A1 inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA]
bafilomycin A1 inhibits the reaction [SLC17A7 protein results in increased uptake of Excitatory Amino Acid Agents]; bafilomycin A1 inhibits the reaction [SLC17A7 protein results in increased uptake of Zinc]; bafilomycin A1 inhibits the reaction [SLC30A3 protein promotes the reaction [SLC17A7 protein results in increased uptake of Zinc]]
bafilomycin A1 promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 protein] bafilomycin A1 results in increased expression of SNAI1 protein
[bafilomycin A1 co-treated with Rotenone] results in increased expression of SNCA protein bafilomycin A1 results in increased expression of SNCA protein
bafilomycin A1 results in increased expression of SQSTM1 protein bafilomycin A1 promotes the reaction [Hydrogen Peroxide results in increased expression of SQSTM1 protein] [Resveratrol co-treated with bafilomycin A1] results in increased expression of SQSTM1 protein; [Silicon Dioxide co-treated with bafilomycin A1] results in increased expression of SQSTM1 protein; [Silicon Dioxide co-treated with Vitamin D co-treated with bafilomycin A1] results in increased expression of SQSTM1 protein; [TNF protein co-treated with bafilomycin A1] results in increased expression of SQSTM1 protein; [Vitamin D co-treated with bafilomycin A1] results in increased expression of SQSTM1 protein; bafilomycin A1 inhibits the reaction [2-chloroethyl ethyl sulfide results in decreased expression of SQSTM1 protein]; bafilomycin A1 inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of SQSTM1 protein]; bafilomycin A1 inhibits the reaction [dactolisib results in decreased expression of SQSTM1 protein]; bafilomycin A1 inhibits the reaction [Dexamethasone results in decreased expression of SQSTM1 protein]; bafilomycin A1 inhibits the reaction [pterostilbene inhibits the reaction [Ethanol results in increased expression of SQSTM1 protein]]; bafilomycin A1 inhibits the reaction [Resveratrol results in increased degradation of SQSTM1 protein]; bafilomycin A1 inhibits the reaction [Sorafenib results in decreased expression of SQSTM1 protein]; bafilomycin A1 promotes the reaction [ginsenoside Rg2 results in decreased expression of SQSTM1 protein]; bafilomycin A1 promotes the reaction [metarrestin results in decreased expression of SQSTM1 protein]; bafilomycin A1 promotes the reaction [Miconazole results in increased expression of SQSTM1 protein]; bafilomycin A1 promotes the reaction [N-Methyl-3,4-methylenedioxyamphetamine results in increased expression of SQSTM1 protein]; bafilomycin A1 promotes the reaction [pachastrissamine analog promotes the reaction [KEAP1 protein binds to SQSTM1 protein]]; Fingolimod Hydrochloride affects the reaction [bafilomycin A1 results in increased expression of SQSTM1 protein]; sodium arsenite promotes the reaction [bafilomycin A1 results in increased expression of SQSTM1 protein] [bafilomycin A1 co-treated with Rotenone] results in increased expression of SQSTM1 protein; [bafilomycin A1 co-treated with Swainsonine] results in increased expression of SQSTM1 mRNA; [bafilomycin A1 co-treated with Swainsonine] results in increased lipidation of SQSTM1 protein; bafilomycin A1 inhibits the reaction [Resveratrol inhibits the reaction [Streptozocin results in increased expression of SQSTM1 protein]]; bafilomycin A1 inhibits the reaction [Sirolimus results in decreased expression of SQSTM1 protein]; decamethrin promotes the reaction [bafilomycin A1 results in increased expression of SQSTM1 protein]; Streptozocin promotes the reaction [bafilomycin A1 results in increased expression of SQSTM1 protein]
bafilomycin A1 promotes the reaction [Lipopolysaccharides results in increased phosphorylation of TBK1 protein]; bafilomycin A1 promotes the reaction [Poly I-C results in increased phosphorylation of TBK1 protein]
bafilomycin A1 results in increased expression of TNF mRNA [TNF protein co-treated with bafilomycin A1] results in increased expression of MAP1LC3B protein alternative form; [TNF protein co-treated with bafilomycin A1] results in increased expression of SQSTM1 protein; resveratrol promotes the reaction [[TNF protein co-treated with bafilomycin A1] results in increased expression of MAP1LC3B protein alternative form]
bafilomycin A1 results in increased expression of TOMM20 protein Triiodothyronine promotes the reaction [bafilomycin A1 results in increased expression of TOMM20 protein]
[bafilomycin A1 co-treated with cobaltous chloride co-treated with TP53 gene mutant form] results in increased activity of CASP3 protein; bafilomycin A1 inhibits the reaction [[cobaltous chloride co-treated with TP53 gene mutant form] results in increased activity of CTSB protein]
bafilomycin A1 affects the reaction [N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide affects the reaction [Glucose affects the phosphorylation of ULK1 protein]]
[Cysteine Proteinase Inhibitors results in decreased activity of USP8 protein] promotes the reaction [bafilomycin A1 results in increased cleavage of PARP1 protein]; bafilomycin A1 promotes the reaction [[Cysteine Proteinase Inhibitors results in decreased activity of USP8 protein] which results in increased cleavage of PARP1 protein]
[bafilomycin A1 co-treated with Vitamin D] results in increased expression of VDR protein; [Silicon Dioxide co-treated with Vitamin D co-treated with bafilomycin A1] results in increased expression of VDR protein
bafilomycin A1 promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of VIM protein] bafilomycin A1 results in increased expression of VIM protein
Heptachlor Epoxide inhibits the reaction [EPHX2 protein results in increased metabolism of stilbene oxide analog]; Heptachlor Epoxide promotes the reaction [EPHX2 protein results in increased metabolism of stilbene oxide]
Heptachlor Epoxide results in decreased phosphorylation of GJA1 protein Heptachlor Epoxide results in decreased expression of GJA1 protein Heptachlor Epoxide results in decreased expression of and results in decreased phosphorylation of GJA1 protein Heptachlor Epoxide results in decreased expression of GJA1 mRNA
Heptachlor Epoxide results in increased expression of PRKCE protein alternative form Heptachlor Epoxide results in decreased expression of PRKCE protein alternative form
Heptachlor Epoxide results in increased expression of TFF1 mRNA ICI 164384 inhibits the reaction [Heptachlor Epoxide results in increased expression of TFF1 mRNA]
saracatinib results in decreased activity of CSK protein saracatinib inhibits the reaction [CSK protein results in decreased expression of CYP7A1 mRNA]
saracatinib inhibits the reaction [Calcitriol results in increased expression of CYP24A1 mRNA]; saracatinib inhibits the reaction [lithocholic acid acetate results in increased expression of CYP24A1 mRNA]
saracatinib results in increased expression of CYP7A1 mRNA saracatinib inhibits the reaction [Calcitriol results in decreased expression of CYP7A1 mRNA]; saracatinib inhibits the reaction [CSK protein results in decreased expression of CYP7A1 mRNA]; saracatinib inhibits the reaction [lithocholic acid acetate results in decreased expression of CYP7A1 mRNA]
saracatinib inhibits the reaction [Calcitriol results in increased phosphorylation of VDR protein]; saracatinib inhibits the reaction [lithocholic acid acetate results in increased phosphorylation of VDR protein]
[venetoclax inhibits the reaction [Daunorubicin results in increased expression of ABCB1 protein]] which results in decreased export of Daunorubicin; venetoclax inhibits the reaction [Daunorubicin results in increased expression of ABCB1 protein]
BBC3 protein affects the susceptibility to venetoclax 2-(4-chlorophenoxy)-N-(4-(2-(4-chlorophenoxy)acetamido)cyclohexyl)acetamide inhibits the reaction [BBC3 protein affects the susceptibility to venetoclax]; BBC3 protein affects the susceptibility to [venetoclax co-treated with pitavastatin]
venetoclax results in decreased activity of BCL2 protein venetoclax results in decreased expression of BCL2 protein [9H-purine-9-propanamine, 6-amino-8-((6-iodo-1,3-benzodioxol-5-yl)thio)-N-(1-methylethyl)- co-treated with venetoclax] results in decreased expression of BCL2 protein; [mivebresib co-treated with venetoclax] results in decreased expression of BCL2 protein
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of BTRC protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of BTRC protein]; [WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of BTRC mRNA; [WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of BTRC protein; [WEHI-539 co-treated with venetoclax] results in decreased expression of BTRC mRNA; [WEHI-539 co-treated with venetoclax] results in decreased expression of BTRC protein; BTRC protein affects the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of PMAIP1 protein]; BTRC protein affects the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of SP1 protein]; BTRC protein affects the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of PMAIP1 protein]; BTRC protein affects the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of SP1 protein]; Chloroquine inhibits the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of BTRC mRNA]; Chloroquine inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of BTRC mRNA]; Chloroquine inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of BTRC protein]; Dactinomycin promotes the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of BTRC mRNA]; Dactinomycin promotes the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of BTRC mRNA]
[venetoclax co-treated with sepantronium] results in increased cleavage of CASP3 protein; venetoclax inhibits the reaction [Arsenic Trioxide results in increased cleavage of CASP3 protein]; venetoclax promotes the reaction [ZCL-082 results in increased cleavage of CASP3 protein]; ZCL-082 promotes the reaction [venetoclax results in increased cleavage of CASP3 protein]
venetoclax results in decreased expression of FLT3 protein 9H-purine-9-propanamine, 6-amino-8-((6-iodo-1,3-benzodioxol-5-yl)thio)-N-(1-methylethyl)- promotes the reaction [venetoclax results in decreased expression of FLT3 protein]; [9H-purine-9-propanamine, 6-amino-8-((6-iodo-1,3-benzodioxol-5-yl)thio)-N-(1-methylethyl)- co-treated with venetoclax] results in decreased expression of FLT3 protein
[venetoclax co-treated with WEHI-539 co-treated with hydroquinone] results in decreased phosphorylation of MAPK1 protein; [venetoclax co-treated with WEHI-539] results in decreased phosphorylation of MAPK1 protein
[venetoclax co-treated with WEHI-539 co-treated with hydroquinone] results in decreased phosphorylation of MAPK3 protein; [venetoclax co-treated with WEHI-539] results in decreased phosphorylation of MAPK3 protein
venetoclax results in increased expression of MCL1 protein venetoclax results in decreased expression of MCL1 protein 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of MCL1 protein]; [mivebresib co-treated with venetoclax] results in decreased expression of MCL1 protein; [sepantronium co-treated with venetoclax] results in decreased expression of MCL1 protein; [WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of MCL1 protein; [WEHI-539 co-treated with venetoclax] results in decreased expression of MCL1 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of MCL1 protein]; Cycloheximide promotes the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of MCL1 protein]; PMAIP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of MCL1 protein]; PMAIP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of MCL1 protein]; SP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of MCL1 protein]; SP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of MCL1 protein]
[venetoclax co-treated with WEHI-539 co-treated with hydroquinone] results in increased expression of NOX4 mRNA; [venetoclax co-treated with WEHI-539 co-treated with hydroquinone] results in increased expression of NOX4 protein; [venetoclax co-treated with WEHI-539] results in increased expression of NOX4 mRNA; [venetoclax co-treated with WEHI-539] results in increased expression of NOX4 protein
[mivebresib co-treated with venetoclax] results in increased cleavage of PARP1 protein; [venetoclax co-treated with sepantronium] results in increased cleavage of PARP1 protein; venetoclax promotes the reaction [ZCL-082 results in increased cleavage of PARP1 protein]; ZCL-082 promotes the reaction [venetoclax results in increased cleavage of PARP1 protein]
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of PMAIP1 protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of PMAIP1 protein]; [WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of PMAIP1 mRNA; [WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of PMAIP1 protein; [WEHI-539 co-treated with venetoclax] results in increased expression of PMAIP1 mRNA; [WEHI-539 co-treated with venetoclax] results in increased expression of PMAIP1 protein; BTRC protein affects the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of PMAIP1 protein]; BTRC protein affects the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of PMAIP1 protein]; Chloroquine inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of PMAIP1 protein]; mithramycin A inhibits the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of PMAIP1 mRNA]; mithramycin A inhibits the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of PMAIP1 protein]; mithramycin A inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of PMAIP1 mRNA]; mithramycin A inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of PMAIP1 protein]; PMAIP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of MCL1 protein]; PMAIP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of MCL1 protein]; SP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of PMAIP1 protein]; SP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of PMAIP1 protein] PMAIP1 protein affects the susceptibility to venetoclax venetoclax results in increased expression of PMAIP1 protein
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of SP1 protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of SP1 protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of SP1 protein]; [WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of SP1 protein; [WEHI-539 co-treated with venetoclax] results in increased expression of and results in increased stability of SP1 protein; BTRC protein affects the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of SP1 protein]; BTRC protein affects the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of SP1 protein]; Chloroquine inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of SP1 protein]; SP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of MCL1 protein]; SP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of PMAIP1 protein]; SP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of MCL1 protein]; SP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of PMAIP1 protein]
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[venetoclax co-treated with WEHI-539 co-treated with hydroquinone] results in decreased expression of SQSTM1 protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[venetoclax co-treated with WEHI-539] results in decreased expression of SQSTM1 protein]; [venetoclax co-treated with WEHI-539 co-treated with hydroquinone] results in decreased expression of SQSTM1 protein; [venetoclax co-treated with WEHI-539] results in decreased expression of SQSTM1 protein; Chloroquine inhibits the reaction [[venetoclax co-treated with WEHI-539] results in decreased expression of SQSTM1 protein]
browse the term
